The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus
The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus
复制标题
DOI：
10.1038/s41409-020-0826-4
复制
发表时间：
2020-02-17
影响因子：
4.8
通讯作者：
Kroeger, Nicolaus
中科院分区：
文献类型：
--
作者：
Passweg, Jakob R.;Baldomero, Helen;Kroeger, Nicolaus
造血细胞移植（HCT）广泛用于造血系统的获得性和先天性疾病。欧洲和相关国家进行的移植数量持续增加，2018年50个国家的701个中心报告了42，901名患者的47，468例HCT [19，630例同种异体（41%）和27，838例自体（59%）]。主要适应症为骨髓恶性肿瘤10，679例（25%; 97%同种异体）、淋巴恶性肿瘤27，318例（64%; 20%同种异体）、实体瘤1625例（4%; 2.9%同种异体）和非恶性疾病3063例（7%; 81%同种异体）。今年的分析重点关注细胞疗法，CAR T细胞疗法从2017年的151例显著增长到2018年报告的301例患者。其他细胞治疗数字显示出不太显著的变化。HCT的重要趋势包括慢性期CML的同种异体HCT增加49%（尽管移植数量仍然很低）和再生障碍性贫血增加24%。在自体HCT中，自身免疫性疾病持续增加（19%），主要是由于多发性硬化症的活动。这份年度报告反映了当前的活动，并强调了重要的趋势，对卫生保健规划很有用。
Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year's analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.